<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330054</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU MRAbdallah</org_study_id>
    <nct_id>NCT03330054</nct_id>
  </id_info>
  <brief_title>Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease</brief_title>
  <official_title>Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohammed Ramadan Abdallah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the frequency and type of eye problem among Type 2 Diabetics with renal&#xD;
      impairment and effect of renal impairment and haemodialysis on diabetic retinopathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease is a descriptive term and is used for deteriorating kidney function of&#xD;
      any underlying cause. Chronic kidney disease implies longstanding (&gt;3 months), potentially&#xD;
      progressive, impairment in renal function.(Kumar &amp; Clark's ., 2016).&#xD;
&#xD;
      Diabetes mellitus is the most common cause of chronic kidney disease in developed countries.&#xD;
      In patients with diabetes, there is a steady advance from microalbuminuria to dipstick&#xD;
      positive proteinuria and a progression to renal failure. (Davidson's.,2014) .The most&#xD;
      commonly diagnosed diabetes-related complications is diabetic retinopathy. Its prevalence&#xD;
      increases with the duration of diabetes. Some 20%of people with type 1 diabetes will have&#xD;
      retinal changes after 10 years, rising to &gt;95% after20 years; 20-30% of people with type 2&#xD;
      diabetes have retinopathy at diagnosis.(Kumar &amp; Clark's ., 2016) .&#xD;
&#xD;
      Also from risk factors of diabetic retinopathy is nephropathy, and if severe, is associated&#xD;
      with worsening of Diabetic retinopathy. Conversely, treatment of renal disease (e.g. renal&#xD;
      transplantation) may be associated with improvement of retinopathy and a better response to&#xD;
      photocoagulation.(Kanaski ,2016) The high burden of ocular disease in Chronic kidney disease&#xD;
      can be explained, in part, by the sharing of risk factors common to both kidney and eye&#xD;
      diseases such as age, smoking, hypertension, diabetes, raised serum cholesterol and obesity.&#xD;
      Ocular diseases may also be directly linked to chronic kidney disease via common pathogenic&#xD;
      pathways, including, atherosclerosis, microangiopathy, inflammation and oxidative stress&#xD;
      (Wong et al., 2014).&#xD;
&#xD;
      In our study we seek to do the following for participants :&#xD;
&#xD;
        1. A detailed history including&#xD;
&#xD;
             1. Age, sex, smoking Habits&#xD;
&#xD;
             2. Duration of diabetes mellitus and treatment.&#xD;
&#xD;
             3. Chronic kidney disease stage by estimated glomerular filtration rate according to&#xD;
                MDRD formula&#xD;
&#xD;
             4. Duration of haemodialysis.&#xD;
&#xD;
             5. Associated co-morbidity as hypertension,&#xD;
&#xD;
             6. Therapeutic history eg; angiotensin converting enzyme, angiotensin II receptor&#xD;
                blocker, amiodarone, erythropoietin.&#xD;
&#xD;
        2. Complete Clinical examination including haemodynamics, complete cardiac, chest,&#xD;
           abdominal, lower limb examination, cranial nerve examination.&#xD;
&#xD;
        3. Complete eye examination including detailed fundus examination, classifying expected eye&#xD;
           problems as:&#xD;
&#xD;
             -  Cataract. - Glaucoma&#xD;
&#xD;
             -  Cranial nerve affection&#xD;
&#xD;
             -  Retinopathy either proliferative, non proliferative or macular oedema.&#xD;
&#xD;
        4. The following investigations will be done:&#xD;
&#xD;
             -  Serum creatinine &amp; Blood Urea for estimation of glomerular filtration rate&#xD;
&#xD;
             -  Glycated haemoglobin (HbA1c).&#xD;
&#xD;
             -  lipogram.&#xD;
&#xD;
             -  Complete blood count&#xD;
&#xD;
             -  ECG&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency Of Eye problems In Type 2 Diabetes with Chronic Kidney Disease</measure>
    <time_frame>2 days for each participant to be assessed</time_frame>
    <description>To evaluate the frequency and type of eye problem among:&#xD;
Type 2 Diabetics not having renal impairment.&#xD;
Type 2 Diabetics with chronic kidney disease not on replacement therapy.&#xD;
Type 2 Diabetics with end stage renal disease on haemodialysis.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Eye Diseases</condition>
  <condition>Renal Impairment</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fundoscope</intervention_name>
    <description>Fundoscope for eye examination</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Group A 50 patients Type 2 Diabetes without renal impairment. from outpatient clinic Group&#xD;
        B 25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy.&#xD;
        (stage I-IV) from outpatient clinic and admitted patient in Luxor International Hospital.&#xD;
&#xD;
        Group C 25 patients Type 2 Diabetes with end-stage renal disease on haemodialysis from&#xD;
        Haemodialysis unit in Luxor International Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  50 patients Type 2 Diabetes without renal impairment.&#xD;
&#xD;
          -  25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy.&#xD;
             (stage I-IV)&#xD;
&#xD;
          -  25 patients Type 2 Diabetes with end-stage renal disease on haemodialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with previous history of eye problems and any systemic disease.&#xD;
&#xD;
          -  Type 1 Diabetics .&#xD;
&#xD;
          -  Acute kidney injury in Diabetics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lobna F El-Toony, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed R Abdallah</last_name>
    <phone>00201011770935</phone>
    <phone_ext>0020952600399</phone_ext>
    <email>drmramadanas33@gmail.com</email>
  </overall_contact>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 4, 2017</last_update_submitted>
  <last_update_submitted_qc>November 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Ramadan Abdallah</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

